RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured.

15 Sep 2011

Henry Ford study identifies 23 microRNAs for laryngeal cancer

A Henry Ford Hospital study has identified 23 microRNAs for laryngeal cancer, a discovery that could yield new insight into what causes certain cells to grow and become cancerous tumors in the voice box.

14 Sep 2011

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011

New treatment strategy for dominant forms of muscular dystrophy

Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.

12 Sep 2011

Dysregulated neuronal RNA transport may cause Fragile X-associated tremor/ataxia syndrome

SUNY Downstate scientist Ilham Muslimov, MD, PhD, along with senior author Henri Tiedge, PhD, professor of physiology and pharmacology and of neurology, published a study suggesting that cellular dysregulation associated with certain neurodegenerative disorders may result from molecular competition in neuronal RNA transport pathways.

8 Sep 2011

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Labcyte Inc., a leader in miniaturization technologies for liquid handling, announced today that Thermo Fisher Scientific, the world leader in serving science, is offering the option for customers to receive siRNA (small-interfering RNA) reagent libraries in Labcyte Echo qualified source plates.

From Thermo Fisher Scientific Inc. 7 Sep 2011

Penn researchers receive NIH grant to continue programs of Musculoskeletal disorders center

Researchers from the Perelman School of Medicine at the University of Pennsylvania have been awarded another five-year, $3.2 million grant from the National Institutes of Health (NIH) to continue the programs of the Penn Center for Musculoskeletal Disorders.

7 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

Researchers discover new genetic defect that can lead to Leigh syndrome

In Leigh syndrome, infants are born apparently healthy only to develop movement and breathing disorders that worsen over time, often leading to death by the age of 3. The problem is that the mitochondria responsible for powering their cells can't keep up with the demand for energy in their developing brains.

7 Sep 2011

IOF presents eight young investigator awards to researchers across the world

Eight IOF Young Investigator Awards were presented by the International Osteoporosis Foundation (IOF) to young researchers from Australia, China, India and Japan, in recognition of their outstanding work. The awards, valued at 1,000 USD each, were awarded to the highest scored abstracts by researchers under the age of 40.

7 Sep 2011

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.

6 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

QIAGEN today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

From QIAGEN Manchester Limited 6 Sep 2011

Scientists discover highly conserved mechanism governing brain development

If you think today's political rhetoric is overheated, imagine what goes on inside a vertebrate embryo. There, two armies whose agendas are poles apart, engage in a battle with consequences much more dire than whether the economy will recover---- they are battling for whether you (or frogs or chickens) will have a forebrain.

3 Sep 2011

Researchers discover why tumors evolve

Like snakes, tumour cells shed their skin. Cancer is not a static disease but during its development the disease accumulates changes to evade natural defences adapting to new environmental circumstances, protecting against chemotherapy and radiotherapy and invading neighbouring organs, eventually causing metastasis.

3 Sep 2011

Chromatin might have another life as direct signaling molecule

Chromatin - the intertwined histone proteins and DNA that make up chromosomes - constantly receives messages that pour in from a cell's intricate signaling networks: Turn that gene on. Stifle that one. But chromatin also talks back, scientists at The University of Texas MD Anderson Cancer Center report today in the journal Cell, issuing orders affecting a protein that has nothing to do with chromatin's central role in gene transcription - the first step in protein formation.

2 Sep 2011

Insight into molecular basis of Enhanced S-Cone Syndrome

A new research report published in The FASEB Journal will help ophthalmologists and scientists better understand a rare genetic disease that causes increased susceptibility to blue light, night blindness, and decreased vision called Enhanced S-Cone Syndrome or Goldman-Favre Syndrome.

2 Sep 2011

Study may help explain plague's rapid evolution and aid in development of therapeutics

In the evolutionary blink of an eye, a bacterium that causes mild stomach irritation evolved into a deadly assassin responsible for the most devastating pandemics in human history. How did the mild-mannered Yersinia pseudotuberculosis become Yersinia pestis, more commonly known as the Plague?

30 Aug 2011

HTG announces availability of qDiscovery miRNA WTA Version 16

HTG Molecular Diagnostics today announced the availability of the qDiscovery miRNA Whole Transcriptome Array (WTA) Version 16, a complete solution for microRNA (miRNA) analysis on any sample type or size.

30 Aug 2011

Specific inhibitor of microRNA-100 can stimulate development of new blood vessels

A specific inhibitor of the small regulatory RNA-molecule "microRNA-100" can be used to stimulate the growth of new blood vessels, if a major artery is chronically occluded.

29 Aug 2011

RNA News and Research

Further Reading

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

Henry Ford study identifies 23 microRNAs for laryngeal cancer

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

New treatment strategy for dominant forms of muscular dystrophy

Dysregulated neuronal RNA transport may cause Fragile X-associated tremor/ataxia syndrome

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Penn researchers receive NIH grant to continue programs of Musculoskeletal disorders center

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Researchers discover new genetic defect that can lead to Leigh syndrome

IOF presents eight young investigator awards to researchers across the world

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

Scientists discover highly conserved mechanism governing brain development

Researchers discover why tumors evolve

Chromatin might have another life as direct signaling molecule

Insight into molecular basis of Enhanced S-Cone Syndrome

Study may help explain plague's rapid evolution and aid in development of therapeutics

HTG announces availability of qDiscovery miRNA WTA Version 16

Specific inhibitor of microRNA-100 can stimulate development of new blood vessels

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo